Mostra 1 - 2 risultati di 2 ricerca 'A. Wiestner', tempo di risposta: 0,02s Raffina i risultati
  1. 1
    P1303: POTENTIATING ANTI-CD20 MONOCLONAL ANTIBODY THERAPY BY TARGETING COMPLEMENT C3 ACTIVATION FRAGMENTS COVALENTLY DEPOSITED ON LYMPHOMA CELLS

    P1303: POTENTIATING ANTI-CD20 MONOCLONAL ANTIBODY THERAPY BY TARGETING COMPLEMENT C3 ACTIVATION FRAGMENTS COVALENTLY DEPOSITED ON LYMPHOMA CELLS di A. Wiestner, S. Baskar, H. Peng, E. Gaglione, M. Lindorfer, R. Taylor, C. Rader

    Pubblicazione 2022-06-01
    Testo
    Articolo
  2. 2
    P649: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-2127, A FIRST-IN-CLASS ORAL BTK DEGRADER WITH IMID-LIKE ACTIVITY, IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL MALIGNANCIES

    P649: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-2127, A FIRST-IN-CLASS ORAL BTK DEGRADER WITH IMID-LIKE ACTIVITY, IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL MALIGNANCIES di A. Mato, A. Danilov, M. R. Patel, M. Tees, I. Flinn, W. Ai, K. Patel, M. Wang, S. M. O’Brien, S. Nandakumar, M. Tan, E. Meredith, M. Gessner, S. Y. Kim, A. Wiestner, W. G. Wierda

    Pubblicazione 2022-06-01
    Testo
    Articolo

Strumenti per la ricerca: